Central Nervous System News and Research

RSS

OECs may hold promise for pediatric cerebral palsy treatment

A unique cell type that supports and surrounds (ensheathes) neurons within the nose (olfactory system) known as olfactory ensheathing cells (OECs), possess the ability to regenerate, are relatively easy to obtain, and have become prime candidates for transplantation to repair a number of lesions in the central nervous system (CNS).

19 Apr 2010

Potential drug to annul ADAM-17 protein activity needed

Over the past four years, in the installations of the Faculty of Medicine, University of Cadiz, a group of researchers, headed by Doctor Carmen Estrada, has been studying neurogenesis - the process of forming new neurons from mother cells - in the adult mammal brain. The purpose of this research project is to contribute to the knowledge of this process with the object of finding some additional mechanism that would facilitate the treatment of pathologies of the central nervous system (CNS) that are suffered in consequence of neuronal death.

19 Apr 2010

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Individuals involved in rescue, recovery, demolition, and clean-up after the World Trade Center (WTC) disaster on September 11, 2001, were exposed to a complex mixture of airborne smoke, dust, combustion gases, acid mists, and metal fumes. The impact of this exposure on responders' upper and lower respiratory function has been well documented, but little is known about its impact on their sensitivity to odor and irritants.

19 Apr 2010

Honey beneficial for treatment of fungating tumor wounds

Surviving cancer is physically and emotionally exhausting. But for many patients, beating the disease itself is just the first hurdle. A second ordeal comes from living with the fungating tumor wounds that accompany various cancers. Aside from the pain they inflict, these wounds often emit a strong and offensive odor. Not only does going into public become potentially embarrassing, but it also can be extremely depressing when even close family members are repulsed by the smell.

17 Apr 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range.

16 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Cegedim Dendrite announces global SaaS CRM agreement with UCB

Cegedim Dendrite, the world's leading provider of life-sciences specific Customer Relationship Solutions, has signed a global SaaS CRM agreement with biopharmaceutical company UCB.

15 Apr 2010

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Tapeworm infections of the brain, which can cause epileptic seizures, appear to be increasing in Mexico and bordering southwestern states, Loyola University Health System researchers report.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Scientists at Birmingham Children's Hospital and the Universities of Nottingham and Southampton have developed new guidelines that should help doctors to diagnose brain tumours in children more quickly.

15 Apr 2010

Investment report on Rexahn Pharmaceuticals

StockPreacher.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

13 Apr 2010

Physicians warn parents on dangers of prescription drug abuse among children

With reports of increased prescription drug overdoses in emergency departments, the nation's emergency physicians are issuing a strong warning to parents about the dangers of abusing prescription drugs, which are now the second most abused drugs, after marijuana. Hospital visits caused by accidental and unintentional prescription drug overdoses went up 37 percent between 1999 and 2006, according to new data released by the American Journal of Preventive Medicine.

13 Apr 2010

Lean mass may decline among Alzheimer's patients

Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Investment report on Somaxon Pharmaceuticals

StockPreacher.com announces an investment report featuring Somaxon Pharmaceuticals, Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

9 Apr 2010

Central Nervous System News and Research

OECs may hold promise for pediatric cerebral palsy treatment

Potential drug to annul ADAM-17 protein activity needed

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Honey beneficial for treatment of fungating tumor wounds

RegeneRx Biopharmaceuticals proposes common stock public offering

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

Study: Atorvastatin may slow down MS progression

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Cegedim Dendrite announces global SaaS CRM agreement with UCB

Tapeworm infections of brain increasing in Mexico and bordering southwestern states

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Investment report on Rexahn Pharmaceuticals

Physicians warn parents on dangers of prescription drug abuse among children

Lean mass may decline among Alzheimer's patients

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Investment report on Somaxon Pharmaceuticals

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News